AstraZeneca and GSK boosted by strong oncology sales
Updated
Updated · Bloomberg · Apr 29
AstraZeneca and GSK boosted by strong oncology sales
14 articles · Updated · Bloomberg · Apr 29
The two largest London-listed drugmakers, AstraZeneca and GSK, report robust growth driven by increased cancer medicine sales.
This surge in oncology revenue highlights the companies' successful focus on cancer treatments, supporting their financial performance amid a competitive pharmaceutical market.
Strong oncology sales reinforce both firms' positions as leading players in the UK pharmaceutical sector, with ongoing innovation in cancer therapies driving investor confidence.
How are strategic acquisitions shaping the future of cancer treatment dominance?
AstraZeneca or GSK: Whose cancer drug pipeline promises greater returns by 2030?
As cancer drug sales soar, will breakthrough treatments become more affordable for patients?
Which company's new antibody-drug conjugates offer the most hope for hard-to-treat cancers?
With a projected $748B market, are we overlooking the risks of an oncology bubble?
Why is the Asia Pacific region poised to become the fastest-growing oncology market?